CliffBio
small molecule

RYTARY

CARBIDOPA; LEVODOPA

Loss of exclusivityDecember 2028latest FDA-listed patent expiry
CompanyImpax Laboratories →View the full company profile on CliffBio

Drug detail

Brand nameRYTARY
Active ingredientCARBIDOPA; LEVODOPA
Strength61.25MG;245MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2015
Marketing statusRX

Listed patents

PatentExpiresType
8377474December 2028product
8454998December 2028product
9089607December 2028product
9463246December 2028product
8557283December 2028product
9901640December 2028product
9533046December 2028product
9089608December 2028product

More from Impax Laboratories

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RYTARY patent cliff — loss of exclusivity December 2028 | CliffBio